• Hims Hers Health is trading 5.2% up at $28.45 as investors buy the recent dip.
  • The rebound follows a multi-day pullback, largely triggered by a Federal Trade Commission (FTC) lawsuit filed on July 29, 2026, alleging data sharing and deceptive practices.
  • This "dip-buying" builds on momentum from a sharp 8.16% rebound on July 30, despite broader weakness in the healthcare sector.